drugset / Trial / NCT04460586
Pharmacokinetics of Omadacycline in Cystic Fibrosis
NaSingle-groupOpen-labelOther
Summary
The purpose of this study is to characterize the pharmacokinetics of intravenous and oral omadacycline in patients with cystic fibrosis.
Timeline
- Start
- 2021-07-01
- Primary completion
- 2023-12-01
- Completion
- 2023-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Omadacycline | Small molecule | 100 mg | Intravenous |
| Subject | Omadacycline | Small molecule | 300 mg | Intravenous |